Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination

  • Sun Young Rha (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Hyun Cheol Chung (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • Received : 2022.11.03
  • Accepted : 2022.12.29
  • Published : 2023.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Gastric cancer is heterogeneous in morphology, biology, genomics, and treatment response. Alterations in human epidermal growth factor receptor 2 (HER2) overexpression, microsatellite instability (MSI) status, programmed death-ligand 1 (PD-L1) levels, and fibroblast growth factor receptor 2 (FGFR2) can be used as biomarkers. Since the combination of fluoropyrimidine/platinum plus trastuzumab that was investigated in the ToGA trial was approved as a standard of care in HER2-positive patients in 2010, no other agents showed efficacy in the first- (HELOISE, LOGiC, JACOB trials) and second- (TyTAN, GATSBY, T-ACT trials) line treatments. Despite the success in treating breast cancer, various anti-HER2 agents, including a monoclonal antibody (pertuzumab), an antibody-drug conjugate (ADC; trastuzumab emtansine [T-DM1]), and a small molecule (lapatinib) failed to translate into clinical benefits until the KEYNOTE-811 (first-line) and DESTINY-Gastri01 (≥second-line) trials were conducted. The incorporation of HER2-directed treatment with immune checkpoint inhibitors in the form of a monoclonal antibody or ADC is now approved as a standard treatment. Despite the promising results of new agents (engineered monoclonal antibodies, bi-specific antibodies, fusion proteins, and small molecules) in the early phase of development, the management of HER2-positive gastric cancer requires further optimization to achieve precision medicine with a chemotherapeutic backbone. Treatment resistance is a complex process that can be overcome using a combination of chemotherapy, targeted agents, and immune checkpoint inhibitors, including novel agents. HER2 status must be reassessed in patients undergoing anti-HER2 treatment with disease progression after the first-line treatment. As a general guideline, patients who need systemic treatment should receive chemotherapy plus targeted agents, anti-angiogenic agents, immune checkpoint inhibitors, or their combinations.

Keywords

References

  1. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018;554:189-194.  https://doi.org/10.1038/nature25475
  2. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-978. 
  3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.  https://doi.org/10.1126/science.3012781
  4. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26:6469-6487. https://doi.org/10.1038/sj.onc.1210477
  5. Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-1052. 
  6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209.  https://doi.org/10.1038/nature13480
  7. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456.  https://doi.org/10.1038/nm.3850
  8. Derks S, de Klerk LK, Xu X, Fleitas T, Liu KX, Liu Y, et al. Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Ann Oncol 2020;31:1011-1020.  https://doi.org/10.1016/j.annonc.2020.04.011
  9. Catenacci DV, Chung HC, Shen L, Moehler M, Yoon HH, Rosales MK, et al. Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open 2022;7:100360. 
  10. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-8874.  https://doi.org/10.1074/jbc.274.13.8865
  11. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004;10:6779-6788.  https://doi.org/10.1158/1078-0432.ccr-04-0112
  12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.  https://doi.org/10.1016/S0140-6736(10)61121-X
  13. Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res 2017;77:5374-5383.  https://doi.org/10.1158/0008-5472.CAN-16-2774
  14. Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, et al. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br J Cancer 2018;119:1487-1494.  https://doi.org/10.1038/s41416-018-0318-0
  15. Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herraez-Baranda LA, et al. HELOISE: phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2017;35:2558-2567.  https://doi.org/10.1200/JCO.2016.71.6852
  16. Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol 2020;38:1919-1927.  https://doi.org/10.1200/jco.19.03077
  17. Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013;19:5552-5556.  https://doi.org/10.1158/1078-0432.CCR-13-0518
  18. Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol 2017;28:855-861.  https://doi.org/10.1093/annonc/mdx002
  19. Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol 2020;21:1066-1076.  https://doi.org/10.1016/s1470-2045(20)30326-0
  20. Moehler MH, Shatarta K, Garrido M, Salmon P, Shen L, Wyrwicz L, et al. First line nivolumab plus chemotherapy versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: expanded efficacy and safety data from Checkmate 649. J Clin Oncol 2021;39:4002.
  21. Catenacci DV, Rosales M, Chung HC, Yoon HH, Shen L, Moehler M, et al. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol 2021;17:1155-1164.  https://doi.org/10.2217/fon-2020-1007
  22. Xu M, Meng X, Lu Y, Wang F. Efficacy and safety of camrelizumab in combination with trastuzumab and chemotherapy as the first-line treatment for patients with HER2-positive advanced gastric cancer. J Gastrointest Oncol 2022;13:548-558.  https://doi.org/10.21037/jgo-21-897
  23. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS8201a, a novel HER2 targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res 2016;22:5097-5108.  https://doi.org/10.1158/1078-0432.ccr-15-2822
  24. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel antihuman epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci 2016;107:1039-1046.  https://doi.org/10.1111/cas.12966
  25. Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer 2019;145:3414-3424.  https://doi.org/10.1002/ijc.32408
  26. Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond) 2021;41:1173-1182.  https://doi.org/10.1002/cac2.12214
  27. Elgersma RC, Coumans RG, Huijbregts T, Menge WM, Joosten JA, Spijker HJ, et al. Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985. Mol Pharm 2015;12:1813-1835.  https://doi.org/10.1021/mp500781a
  28. Hamblett KJ, Hammond PW, Barnsher SD, Fung VK, Davis RH, Wickman GR, et al. ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res 2018;78:3914. 
  29. Hamilton EP, Patel MR, Pegram MD, Tan AR, Storniolo AM, Li J, et al. A phase 1 study to evaluate the safety, pharmacokinetics, immunogenicity, and anti-tumor activity of MEDI4276 in patient with selected HER2-expressing advanced solid tumors. J Clin Oncol 2016;34:TPS632. 
  30. Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol 2015;71:444-452.  https://doi.org/10.1016/j.yrtph.2015.01.014
  31. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol 2014;32:2039-2049.  https://doi.org/10.1200/JCO.2013.53.6136
  32. Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2 - amplified esophagogastric cancer. Cancer Discov 2019;9:199-209.  https://doi.org/10.1158/2159-8290.CD-18-0598
  33. Chen Z, Xu Y, Gong J, Kou F, Zhang M, Tian T, et al. Pyrotinib combined with CDK4/6 inhibitor in HER2- positive metastatic gastric cancer: a promising strategy from AVATAR mouse to patients. Clin Transl Med 2020;10:e148. 
  34. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open 2017;2:e000279. 
  35. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenic alterations in ERBB2/ HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 2015;20:7-12.  https://doi.org/10.1634/theoncologist.2014-0234
  36. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer 2017;76:100-109. https://doi.org/10.1016/j.ejca.2017.02.013
  37. Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci 2018;109:2349-2357.  https://doi.org/10.1111/cas.13663
  38. Chung H, Lee K, Kim W, Gainor J, Lakhani N, Chow L, et al. ASPEN-01: a phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab, and paclitaxel in patients with secondline HER-2 positive advanced gastric or gastroesophageal junction cancer. Ann Oncol 2021;32:S215-S216.  https://doi.org/10.1016/j.annonc.2021.05.055
  39. Denlinger C, Maqueda M, Watkins D, Sym SJ, Bendell JC, Park SH. Randomized phase 2 study of paclitaxel, trastuzumab, with or without MM-111 in HER2 expressing gastroesophageal cancers. J Clin Oncol 2016;34:4043. 
  40. Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 2021;12:81. 
  41. Lee JB, Kwon WS, Kim HS, Jung M, Kim S, Park M, et al. First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer. J Clin Oncol 2020;38:4534. 
  42. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 2014;110:1163-1168.  https://doi.org/10.1038/bjc.2014.18
  43. Ter Veer E, Creemers A, de Waal L, van Oijen MG, van Laarhoven HW. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: a meta-analysis. Int J Cancer 2018;143:438-448.  https://doi.org/10.1002/ijc.31325
  44. Al-Batran SE, Moorahrend E, Maintz C, Goetze TO, Hempel D, Thuss-Patience P, et al. Clinical practice observation of trastuzumab in patients with human epidermal growth receptor 2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. Oncologist 2020;25:e1181-e1187.  https://doi.org/10.1634/theoncologist.2020-0109
  45. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235.  https://doi.org/10.1016/S1470-2045(14)70420-6
  46. Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 2020;23:510-519.  https://doi.org/10.1007/s10120-019-01034-7
  47. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013. 
  48. Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastrooesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017;18:640-653.  https://doi.org/10.1016/S1470-2045(17)30111-0
  49. Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. Gastric Cancer 2019;22:803-816.  https://doi.org/10.1007/s10120-018-00923-7
  50. Van Cutsem E, Di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Ann Oncol 2021;32:S1283-S1346.  https://doi.org/10.1016/j.annonc.2021.08.2135
  51. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtean in previously treated HER2-positive gastric cancer. N Engl J Med 2020;382:2419-2430. https://doi.org/10.1056/NEJMoa2004413
  52. Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan (T-Dxd; DS8201a) in patients with HER2-low, advanced gastric or gastropsophageal junction (GEJ) adenocarcinoma; Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINYGastric01 study. Ann Oncol 2020;31:S899-S900.  https://doi.org/10.1016/j.annonc.2020.08.1928
  53. Banerji U, van Herpen CM, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 doseescalation and dose-expansion study. Lancet Oncol 2019;20:1124-1135.  https://doi.org/10.1016/s1470-2045(19)30328-6
  54. Zhang Y, Qiu M, Wang J, Zhang Y, Yuan X, Zhang T, et al. A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01). J Clin Oncol 2021;39:e16059. 
  55. Pegram MD, Hamilton EP, Tan AR, Storniolo AM, Balic K, Rosenbaum AI, et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol Cancer Ther 2021;20:1442-1453.  https://doi.org/10.1158/1535-7163.MCT-20-0014
  56. Fuchs CS, Tomasek J, Cho JY, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.  https://doi.org/10.1016/S0140-6736(13)61719-5
  57. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal unction. J Clin Oncol 2016;34:1448-1454.  https://doi.org/10.1200/JCO.2015.63.5995
  58. Kang YK, Kang WK, Di Bartolomeo M, Chau I, Yoon HH, Cascinu S, et al. Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/ metastatic gastric cancer who failed ≥2 prior chemotherapy regimens. Ann Oncol 2019;30:v877-v878.  https://doi.org/10.1093/annonc/mdz394.034
  59. Xu J, Zhang Y, Wu J, Xu N, Ying J, Xiang X, et al. The preliminary efficacy of KN026 (anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression. J Clin Oncol 2021;39:e16005. 
  60. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015;51:482-488.  https://doi.org/10.1016/j.ejca.2014.12.015
  61. Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer 2016;16:68. 
  62. Takahari D, Chin K, Ishizuka N, Takashima A, Minashi K, Kadowaki S, et al. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naive, HER2-positive advanced gastric cancer. Gastric Cancer 2019;22:1238-1246.  https://doi.org/10.1007/s10120-019-00973-5
  63. Xue C, Xu YH. Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: a systematic review and meta-analysis of randomized controlled trial. Medicine (Baltimore) 2022;101:e29992. 
  64. Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martinez E, et al. Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 2019;83:1175-1181.  https://doi.org/10.1007/s00280-019-03820-7
  65. Li Q, Lv M, Jiang H, Wang Y, Yu S, Li W, et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol 2020;146:287-295.  https://doi.org/10.1007/s00432-019-03060-5
  66. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology, Gastric Cancer. Version 2. Plymouth Meeting (PA): NCCN; 2020.
  67. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v38-v49.  https://doi.org/10.1093/annonc/mdw350
  68. Dijksterhuis WP, Verhoeven RH, Meijer SL, Slingerland M, Mohammad NH, de Vos-Geelen J, et al. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide populationbased cohort study. Gastric Cancer 2020;23:579-590.  https://doi.org/10.1007/s10120-020-01039-7
  69. Koo DH, Ryu MH, Lee MY, Chae H, Kim EJ, Moon MS, et al. Trends in chemotherapy patterns and survival of patients with advanced gastric cancer over a 16-year period: impact of anti-HER2-targeted agent in the real-world setting. Cancer Res Treat 2021;53:436-444.  https://doi.org/10.4143/crt.2020.725
  70. Kang YK, Rha SY, Tassone P, Barriuso J, Yu R, Szado T, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer 2014;111:660-666.  https://doi.org/10.1038/bjc.2014.356
  71. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 2018;19:1372-1384.  https://doi.org/10.1016/S1470-2045(18)30481-9
  72. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC--a randomized phase III trial. J Clin Oncol 2016;34:443-451. 
  73. Zarkavelis G, Samantas E, Koliou GA, Papadopoulou K, Mauri D, Aravantinos G, et al. AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Acta Oncol 2021;60:785-793.  https://doi.org/10.1080/0284186X.2021.1912822
  74. Ku G, Elimova E, Denlinger CS, Mehta R, Lee KW, Iqbal S, et al. 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Ann Oncol 2021;32:S1044-S1045.  https://doi.org/10.1016/j.annonc.2021.08.1489
  75. Meric-Bernstam F, Hamilton EP, Beeram M, Hanna DL, El-Khoueiry AB, Kang YK, et al. Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA): results from a phase 1 study. J Clin Oncol 2021;39:164. 
  76. Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an openlabel, single-arm, phase 2 trial. Lancet Oncol 2020;21:821-831.  https://doi.org/10.1016/s1470-2045(20)30169-8
  77. Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che J, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun 2022;13:6002. 
  78. Janjigian YY, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-730.  https://doi.org/10.1038/s41586-021-04161-3
  79. Stein A, Paschold L, Tintelnot J, Goekkurt E, Henkes SS, Simnica D, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2- positive esophagogastric adenocarcinoma. JAMA Oncol 2022;8:1150-1158.  https://doi.org/10.1001/jamaoncol.2022.2228
  80. Lee KW, Bai LY, Jung M, Ying J, Im YH, Oh DY, et al. Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study. J Clin Oncol 2022;40:4032. 
  81. Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, et al. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study. Invest New Drugs 2016;34:119-128. https://doi.org/10.1007/s10637-015-0309-4
  82. Enzinger PC, Abrams TA, Chan JA, McCleary NJ, Zheng H, Lee E. Multicenter phase 2: capecitabine, oxaliplatin, bevacizumab, trastuzumab for patients with metastatic esophagogastric cancer (MEGCA). J Clin Oncol 2015;33:4038. 
  83. Catenacci DVT, Kang YK, Yoon HH, Shim BY, Kim ST, Oh DY, et al. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A. ESMO Open 2022;7:100563. 
  84. Gong J, Shen L, Luo S, Dong Z, Liu D, An S, et al. 1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors. Ann Oncol 2021;32:S1042. 
  85. Janjigian YY, Viglianti N, Liu F, Mendoza-Naranjo A, Puvvada S. A phase Ib/II, multicenter, open-labeled, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINYGastric03). Ann Oncol 2020;31:S930-S931.  https://doi.org/10.1016/j.annonc.2020.08.2006
  86. Strickler JH, Nakamura Y, Yoshino T, Catenacci DV, Janjigian YY, Barzi A, et al. MOUNTAINEER02: phase II/III study of tucatinib, trastuzumab, ramucirumab and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma-trial in progress. J Clin Oncol 2021;39:TPS252. 
  87. Kurokawa Y, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer 2015;18:691-697.  https://doi.org/10.1007/s10120-014-0430-7
  88. Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, et al. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013;49:1448-1457.  https://doi.org/10.1016/j.ejca.2012.10.018
  89. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.  https://doi.org/10.1111/j.1365-2559.2008.03028.x
  90. Haffner I, Schierle K, Raimundez E, Geier B, Maier D, Hasenauer J, et al. HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol 2021;39:1468-1478.  https://doi.org/10.1200/JCO.20.02761
  91. Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011;13:179-184.  https://doi.org/10.1007/s12094-011-0637-6
  92. Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, et al. Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer. Clin Cancer Res 2015;21:2520-2529.  https://doi.org/10.1158/1078-0432.ccr-14-2659
  93. Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, et al. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol 2018;53:1186-1195.  https://doi.org/10.1007/s00535-018-1464-0
  94. Park SR, Park YS, Ryu MH, Ryoo BY, Woo CG, Jung HY, et al. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2- negative primary tumours: results of GASTric cancer HER2 reassessment study 1 (GASTHER1). Eur J Cancer 2016;53:42-50.  https://doi.org/10.1016/j.ejca.2015.09.018
  95. Cho EY, Park K, Do I, Cho J, Kim J, Lee J, et al. Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol 2013;26:677-684.  https://doi.org/10.1038/modpathol.2012.205
  96. Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer 2019;22:527-535.  https://doi.org/10.1007/s10120-018-0891-1
  97. Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer 2018;88:92-100. https://doi.org/10.1016/j.ejca.2017.10.032
  98. Maron SB, Chase LM, Lomnicki S, Kochanny S, Moore KL, Joshi SS, et al. Circulating tumor DNA sequencing analysis of gastroesophageal adenocarcinoma. Clin Cancer Res 2019;25:7098-7112.  https://doi.org/10.1158/1078-0432.ccr-19-1704
  99. Mao L, Sun AJ, Wu JZ, Tang JH. Involvement of microRNAs in HER2 signaling and trastuzumab treatment. Tumour Biol 2016;37:15437-15446.  https://doi.org/10.1007/s13277-016-5405-3
  100. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010;28:4390-4399. https://doi.org/10.1200/JCO.2009.27.6360